NA
AZN icon

Navellier & Associates’s AstraZeneca AZN Stock Holding History

Navellier & Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,106
Closed -$1.11M – 277
2020
Q3 		$1.11M Buy
10,106
+30
+0.3% +$3.34K 0.24% 99
2020
Q2 		$1.07M Buy
+10,076
New +$1.04M 0.25% 94
2019
Q2 		– Sell
-20,254
Closed -$1.64M – 273
2019
Q1 		$1.64M Sell
20,254
-5
-0% -$394 0.25% 104
2018
Q4 		$1.54M Buy
+20,259
New +$1.58M 0.26% 85
2015
Q4 		– Sell
-16
Closed -$1K – 233
2015
Q3 		$1K Sell
16
-3,896
-100% -$256K ﹤0.01% 301
2015
Q2 		$249K Buy
3,912
+282
+8% +$19.3K 0.02% 309
2015
Q1 		$248K Sell
3,630
-229
-6% -$15.9K 0.02% 303
2014
Q4 		$272K Sell
3,859
-28
-0.7% -$2K 0.01% 271
2014
Q3 		$278K Buy
+3,887
New +$285K 0.01% 269

Other funds holding AZN

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Navellier & Associates's AZN Position: Q4 2020 in Review

Navellier & Associates sold out of AstraZeneca (AZN) in Q4 2020, closing a stake of 10,106 shares — an estimated $1.11M sold.

Navellier & Associates first reported a position in AZN in Q3 2014 and held it in 9 quarters. The position peaked at $1.64M in Q1 2019. 787 funds tracked by Wall St. Rank hold AZN as of Q4 2020.

  • Navellier & Associates reported no remaining AstraZeneca position as of Q4 2020 after selling out during the quarter.
  • Navellier & Associates sold 10,106 AstraZeneca shares in Q4 2020, an estimated $1.11M.
  • Navellier & Associates first reported a position in AstraZeneca in Q3 2014 and held it in 9 quarters.
  • Navellier & Associates's AstraZeneca position peaked at $1.64M in Q1 2019.
  • 787 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2020.

Based on Navellier & Associates's 13F filing for Q4 2020, filed 5 Feb 2021.